Inpharmatica Ltd has announced that Japanese pharmaceutical company, Mochida, has licensed Admensa Interactive, a suite of predictive drug absorption, distribution, metabolism and excretion models and compound prioritisation tools.
Mochida is the second Japanese company to license Admensa Interactive, Daiichi being the other. This latest customer further endorses the worldwide success of this suite since its launch earlier in the year.
Pharmaceutical companies large and small now use Admensa in the US, Europe and Japan. Under the terms of this new agreement, Mochida will receive a multi-user license to Admensa Interactive.
Admensa Interactive is an integral component of Inpharmatica's gene-to-candidate technology platform, which integrates biology- and chemistry-based drug discovery activities.
This platform optimises target selection based on druggability, and enables rapid identification of hits and selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics and clinical indication.
The agreement was secured in conjunction with PharmaDesign, Inpharmatica's sales and marketing partner in Japan.
John Lisle, CEO of Inpharmatica, said, “Admensa Interactive continues to go from strength to strength, making a valuable contribution to our revenue stream in the very short time since its launch as a product offering. This is our first agreement with Mochida and we are delighted to have them as a customer.”